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Background: The effectiveness of multiple interventions in asthma and chronic obstructive
pulmonary disease (COPD) is unclear.
Objective: To examine the effectiveness of multiple interventions as compared to single inter-
ventions or usual care on health outcomes and health care utilisation within the context of
integrated disease management in asthma and COPD.
Methods: MEDLINE and the Cochrane Library (1995eMay 2008) were searched for controlled
trials. Two reviewers independently extracted data and assessed study quality. Meta-analyses
were performed on quality of life and health care utilisation data. Furthermore, the effects of
multiple interventions versus single interventions and usual care were assessed qualitatively.
Results: Of the 36 studies included, 17 targeted double interventions (patient-related and or-
ganisational interventions); 19 studies performed triple interventions (patient-related, profes-
sional-directed and organisational interventions). They were heterogeneous in terms of
(combinations of) interventions, outcomes measured, study design and setting. Pooled data
showed that studied disease management programmes significantly improved quality of life
on several domains. Patients within triple intervention programmes had less chance of at least
one hospital admission compared with usual care. No significant effects were found in number
of emergency department visits. Qualitative analyses revealed positive trends on process
improvements and satisfaction. Inconclusive results were reported on symptoms; no effects
were found in lung function.niversity Medical Centre, Institute of Health Policy and Management, P.O. Box 1738, 3000 DR
1 10 408 8541; fax: þ31 10 408 9094.
usmc.nl (K.M.M. Lemmens).
8 Elsevier Ltd. All rights reserved.
Disease-management interventions in asthma and COPD 671Conclusion: In spite of the heterogeneity of disease management studies in asthma and COPD
care, this review showed promising improvements in quality of life and reductions in hospita-
lisations, especially for triple intervention programmes.
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Chronic conditions account for more than 50% of the global
disease burden, and this figure is projected to rise.1 Among
the most common chronic diseases worldwide are asthma
and chronic obstructive pulmonary diseases (COPD). These
respiratory diseases represent an enormous burden on
individuals, families and societies, by their impact on quality
of life and health resource utilisation, as well asmortality.2,3
Yet, health care systems are often not organised to provide
effective and efficient care for chronic health problems.4
The causes of chronic conditions are complex and responses
to patients’ needs therefore should be multifaceted and
multi-institutional.5 Disease management has been intro-
duced as the answer to these demands.6e8
Disease management is a concept by which care delivery
is better coordinated through the integration of several
components across the entire delivery system and the
application of tools specifically designed for the population
in question, e.g. guidelines, education, information
systems.9 The Disease Management Association of America
(DMAA)10 defined disease management as: ‘‘a system of
coordinated health care interventions and communications
for populations with conditions in which patient self-care
efforts are significant’’. There are high expectations for
disease management; it is expected to improve quality and
efficacy of care for patients with chronic diseases. Disease
management supports the use of multiple interventions,
defined as combinations of at least two of three types of
intervention: patient-related, professional-directed and
organisational interventions, according to CochraneEffective Practice and Organisation of Care (EPOC).11,12 Key
to disease management is therefore to involve the imple-
mentation and integration of combined interventions.13 But
evidence on the effectiveness of combined interventions in
the care continuum is scattered and an overview on the state
of the art in asthma and COPD is lacking. The question
addressed in this paper is: ‘‘what is the effect of the use of
multiple interventions within the context of integrated
disease management in asthma and COPD’’.
Current literature contains evidence implying improve-
ments in health care as a result of multiple interventions.
Grol14 concludes that multifaceted strategies e combining
different approaches and targeting different barriers to
improvement e are in general more effective than indi-
vidual approaches. He assumes this will probably hold for
disease management too. The chronic care model (CCM)15,16
also emphasises a multifaceted approach, supposedly
leading to healthier patients, more satisfied professionals
and lower costs.6,17 Several systematic reviews across
a number of chronic diseases (e.g. diabetes, heart failure)
confirm positive effects on quality of care.18e22 But, many
studies have focused on the effects of interventions solely
directed either at the patient23e26 or the professional.27e32
So far, these interventions have only been partly successful.
Weingarten and colleagues33 conclude from a meta-analysis
that most disease management programmes directed at
either professionals or patients are associated with
improvements in care. However, this analysis solely covered
single interventions within disease management pro-
grammes; the effectiveness of the combined interventions
was left out of consideration. A systematic review on the
Table 1 Observed EPOC definitions of interventions in asthma and COPD care.
Patient education: Interventions designed to promote
increased understanding of a target condition or to
teach specific prevention or treatment strategies, or
specific in-person patient education (e.g., individual
or group sessions with diabetes nurse educator;
distribution of printed or electronic educational
materials). Interventions with patient education were
included only if they also included at least 1 other
strategy related to clinician or organisational change.
Expansion or revision of professional roles: Changes to the
structure or organisation of the primary health care team:
 Adding a team member or ‘‘shared care,’’ e.g., routine visits
with personnel other than the primary physician (including
physician or nurse specialists in COPD care, pharmacists).
 Expansion or revision of professional roles (e.g., nurse or
pharmacist plays more active role in patient monitoring).
Professional education: Interventions designed to
promote increased understanding of principles guiding
clinical care or awareness of specific
recommendations for a target condition or patient
population (e.g. educational meetings, active
distribution of educational materials, and educational
outreach visits).
Case management: Any system for coordinating diagnosis,
treatment, or ongoing patient management (e.g., arrangement
for referrals, follow-up of test results) by a person or
multidisciplinary team in collaboration with or supplementary
to the primary care clinician.
672 K.M.M. Lemmens et al.effectiveness of the CCM in COPD patients focussed on
interventions including one ormore components, but did not
look at combinations of interventions. Studies with two or
more components had lower health care use compared with
controls. Although previous reviews cover a wide range of
interventions, little is known about the effectiveness of
combined disease management components in asthma and
COPD care. This review aims to understand the effective-
ness of multiple disease management interventions in
improving care and cost-effectiveness for patients with
asthma or COPD.
Methods
Identification of studies
We included studies that evaluated the effectiveness of
disease management programmes consisting of multiple
interventions targeted at patients aged 16 years with
a principal diagnosis of asthma or COPD. Studies were
included if they met the following methodological criteria:
experimental, randomised controlled trials (RCTs) and
controlled clinical trails (CCTs), or quasi-experimental,
controlled before and after studies (CBAs) or time series
designs (ITS). The control group needed to have been
provided usual care or single intervention. Studies were
included if they reported any objective measure of
outcomes reflecting the primary goals of disease manage-
ment, i.e. to promote, maintain and enhance the health of
patients. Studies therefore needed to provide details on
clinical outcomes, quality of life, health care utilisation,
and/or patient satisfaction.10
According to EPOC,11 an intervention was classified as
‘patient’ when targeting patient behaviour, such as patient
education, or self-management interventions; ‘profes-
sional’ when aiming at professional practice behaviour, for
example professional education, audit and feedback;
‘organisational’ when interfering in the structure or orga-
nisation of care, for instance revision of professional roles,
or arrangements for follow-up (Table 1). Since the focus of
the study was on multiple interventions within the contextof disease management, studies on the effects of single
interventions versus usual care were excluded. Moreover,
pulmonary rehabilitation programmes were defined as
single intervention, since they already are a part of the
organisational structure of care, and therefore excluded.
Literature search
Searches of MEDLINE (1995eMay 2008) and the Cochrane
Library (1995eMay 2008) were undertaken. Studies published
before 1995 were not considered for inclusion, as it was not
until 1995beforediseasemanagement appeared frequently in
the medical literature.13 The following key words (Medical
Subject Headings) were entered: disease management,
disease state management, delivery of integrated health
care, comprehensive health care, patient care planning,
primary health care, patient care team, critical pathways,
case management, continuity of patient care, practice
guidelines, guidelines, clinical protocols, patient education,
self-care, reminder systems, health education, health
promotion, community health planning, ambulatory care,
feedback, reminder or monitoring33 in combination with
asthma and COPD specific terms. These all aimed to identify
studiesevaluating theeffectivenessofmultiple interventions.
Methods of the review
Potentially relevant studies retrieved from the electronic
searches were independently screened for eligibility (KL
and AN). Next, three reviewers (KL, AN and RH) indepen-
dently reviewed the selected studies and extracted data
with the use of a standardised abstraction form. Data were
collected which described the interventions, methods,
sample size, population characteristics, setting, and
measures of programme effects on processes and outcomes
of care from unmasked articles that met the inclusion
criteria. Where possible, data were tabulated in terms of
means  SD for patient outcomes and proportions for
process measures; other data were presented as reported
in the original sources. Any discrepancies between
reviewers were resolved by discussion.
Initial search
(N = 2414)
Title accept
(N = 680)
Title reject (N = 1734)
Reason:
1: 502
2: 829
3: 403
4: 0
5: 0
Abstract reject (N = 409)
Reason:
1: 141
2: 86
3: 112
4: 56
5: 14
Abstract accept
(N = 320)
Paper reject (N = 271)
Reason:
1: 12
2: 16
3: 188
4: 27
5: 28
Cochrane search/
secondary references
(N = 49)
Quality accept
(N = 40)
= 36 studies
Quality reject
(N = 9)
Exclusion criteria for systematic review:
2. Reviews, or editorials or case studies
4. No outcomes reported
5. Study design not meeting inclusion criteria 
Paper accept
(N = 49)
1. Condition/ population not meeting inclusion
criteria
procedure trials (not disease management)
3. Single intervention study, drug or
Figure 1 Selection process for including studies in systematic review.
Disease-management interventions in asthma and COPD 673Study quality was assessed with the Health Technology
Assessment-Disease Management (HTA-DM) instrument
developed by Steuten et al.34 The scope of this instrument
comprises quasi-experimental and experimental studies as
well as controlled, uncontrolled and observational studies.34
The instrument includes four components, namely, study
population, description of the intervention,measurement of
outcomes, and data analysis/presentation of data. Method-
ological quality is scored between 0 and 100 points with
scores <50 points indicating inferior quality and 70 points
indicating good quality.35 Studies of inferior quality were
excluded from this review. The HTA-DM is a reliable instru-
ment for methodological quality assessment of HTA of
disease management.34
Data analysis
Given the likely heterogeneity of the studies, we performed
a qualitative assessment of the effects of studies, based
upon the combination of interventions, study quality and
population differences. Potential differences were ana-
lysed by preparing tables to examine the size of observed
effects relative to these variables. When possible, meta-
analyses were performed, using RevMan 4.2.36 Data were
pooled for the Asthma Quality of Life Questionnaire (AQLQ)
in pharmacist disease management programmes, and the
St. George’s Respiratory Questionnaire (SGRQ), emergency
department visits and hospital admissions in COPD disease
management programmes. Outcomes were analysed as
continuous variables using standard statistical techniques
(weighted mean difference (WMD)) and with dichotomous
outcomes pooled odds ratios (OR) were calculated. Both
combined with a fixed effect model and 95% confidence
intervals were calculated as appropriate. Statistical varia-
tion between study findings was explored using the I2
statistical measurement.37Results
Description of studies
Fig. 1 shows the flow of papers through the review. Overall,
2414 references published from January 1995 to May 2008
were identified; 680 were accepted for further screening.
After reading titles and abstracts 409 papers were excluded,
leaving 271 articles for a full-text review. Screening of the
Cochrane Library and references resulted in another 49
potentially relevant articles. Of all 320 articles, 271 (85%) did
not meet the inclusion criteria. Another nine studies were
excluded due to inferior methodological quality.38e46 Even-
tually, 36 studies47e86 (40 papers) were identified asmultiple
intervention studies on asthma and/or COPD; 18 of which
focused on COPD, 16 on asthma, and two on both diseases.
Fourteen studies had ‘good’ methodological quality (70
points)51e53,58,60,63,70,73,77,79,82,84e86; 22 scored between 50
and 69 points and were therefore considered of ‘moderate’
quality.47e49,54e56,61,62,64,65,67e69,71,72,74e76,78,80,81,83
We present results based on combinations of interven-
tions as outlined in the protocol. Seventeen studies used
both patient-related and organisational interventions51,55,
56,61,63,64,67,70,72,73,75,77,78,81e84 and another 19 used triple
interventions (patient-related, professional-directed, and
organisational).47e49,52e54,58,60,62,65,68,69,71,74,76,79,80,85,86 No
studies that combined patient-related and professional-
directed or professional-directed and organisational
interventions passed the selection criteria (Table 2). As
expected, the intervention groups were generally
compared to control patients receiving ‘usual care’.
Control patients in three studies received patient educa-
tion55,78,81; another two studies used two control groups:
one given usual care and one given patient education.54,86
Most studies reported quality of life and health care
utilisation measures. Instruments for measurement of
Table 2 Key Features of Studies Included in a Systematic Review of Multiple Interventions in Patients with Asthma and COPD
Study Setting Studya
design/quality
Interventions Follow-up
(months)b
Outcomec/process
indicatorsd
Resultse
Multiple interventions versus usual care
Aiken et al., 2005
‘‘Intensive Home-based
Case Management’’
COPD patients in a
hospice >18 years with
an estimated 2 year life-
expectancy, Phoenix,
Arizona (U.S.)
RCT
Moderate
I: Provider education,
patient education,
continuity of care (case
management) (NZ33)
C: Usual care (NZ28)
9 QOL: SF36 (8 domains)
HCU: ED
PROCESS: Behaviour;
Knowledge
Sign. better on 3 domains:
Physical functioning,
General health and
Vitality
NS
Sign. better outcomes on
self-management of illness
and knowledge on illness
Armour et al., 2007
‘‘Pharmacy Asthma Care
Programme’’
Asthma patients 18e75
registered in a pharmacy
in New South Wales,
Victoria and Queensland
(Australia)
RCT
Moderate
I: Provider education,
patient education,
expansion or revision of
professional roles
(pharmacist plays more
active role in patient
monitoring) (NZ191)
C: Usual care (NZ205)
6 LUNG: FEV1
SYMP: Perceived Control
of Asthma (PCAQ)
QOL: AQLQ (4 domains)
PROCESS: Knowledge;
Technique; Behaviour
NS
Sign. better asthma
control
Sign. more beneficial
effects in Total score
Sign. more asthma
knowledge; Sign. increase
of correct inhalation
technique and usage
action plan (no data
control)
Barbanel et al., 2003
‘‘Community Pharmacist-
based Programme’’
Adults, 18e65, with a
general practitioner
diagnosis of asthma who
regularly visited the
pharmacy for collection
of prescribed medication
(U.K.)
RCT
Moderate
I: Provider education,
patient education,
expansion or revision of
professional roles
(pharmacist plays more
active role in patient
monitoring) (NZ12)
C: Usual care (NZ12)
3 SYMP: North of England
Symptoms Questionnaire
Sign. better symptom
score
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Bourbeau et al., 2003
Gadoury et al., 2005
Bourbeau et al., 2006
‘‘Multi-component self-
Management
Programme’’
COPD patients 50 years
in 7 hospitals with
advanced COPD with at
least 1 hospitalisation for
exacerbation in the
previous year (Canada)
RCT
Good
I: Patient education,
continuity of care (case
management) (NZ96)
C: Usual care (NZ95)
12 LUN FEV1
QOL SGRQ (4 domains)
SYM 6MWT; MRC;
Spu m; Exacerbations
HCU Hosp; ED; Cost
NS
Sign. better on Impact
domain, other domains NS
NS; NS; NS; Borderline
sign. more decrease in No.
of exacerbations
Sign. more reduction in
No. of hospitalisations
(acute exacerbations/all
cause), frequency
hospitalised, No. of
hospital days; Reduction in
emergency visits (acute
exacerbations) and
scheduled GP visits; cost
savings with increased
patient caseload and rising
costs of hospitalisation.
24 HCU Hosp; ED Stat. sign. and clinically
relevant reduction in all-
cause hospitalisations and
in all-cause emergency
visits
Casas et al., 2006
‘‘Integrated Care’’
COPD patients recruited
in two tertiary hospitals
immediately after the
patients’ hospital
discharge for an
exacerbation >48 hours
(Spain and Belgium).
RCT
Good
I: Provider education,
self-management,
continuity of care (case
management; follow-up)
(NZ65)
C: Usual care (NZ90)
12 HCU Readm; Visits Significantly lower No. of
readmissions, rate of
readmission, and mean
No. of readmissions; NS
(continued on next page)
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Table 2 (continued)
Study Setting Studya
design/quality
Interventions Follow-up
(months)b
Outcomec/process
indicatorsd
Resultse
Cordina et al., 2001
‘‘Community Pharmacist-
based Programme’’
Patients 16 registered
at the asthma clinic
cared for by community
pharmacies (Malta)
RCT
Good
I: Provider education,
patient education,
expansion or revision of
professional roles
(pharmacist plays more
active role in patient
monitoring) (NZ86)
C: Usual care (NZ66)
12 LUNG: PEFR
QOL: SF36 (8 domains);
LWAQ (11 domains)
SYMP: Wheeze
QOC: Satisfaction
HCU: Hosp; Days off
PROCESS: Technique;
Compliance
NS
Sign. better on Vitality
domain, other domains NS;
Borderline sign. better
Total score
Sign. more patients
reported no wheezing
Sign. more patients
reported approachable
pharmacist/questioned
their pharmacist
Sign. fewer self-reported
hospitalisations; NS
Sign. higher improved
inhaler technique; NS
Coultas et al., 2005
‘‘Nurse-Assisted Home
Care’’
COPD patients in primary
care clinics associates
with an urban academic
health center, aged 45
cared for by primary care
physicians (U.S.)
RCT
Moderate
I: Provider education,
patient education,
continuity of care
(follow-up) (NZ72)
C: Usual care (NZ73)
6 QOL: SF36; SGRQ; Illness
intrusiveness scale
HCU: ED; Hosp; Visits
NS; NS; Sign. more
improvement in perceived
illness intrusiveness
NS; NS; NS
Egan et al., 2002
‘‘Nursing-Based Case
Management’’
COPD patients 18
years, admitted to a
major private hospital
(Australia)
RCT
Moderate
I: Patient education,
continuity of care (case
management) (NZ33)
C: Usual care (NZ33)
1,5 QOL: SGRQ (4 domains);
HADS (2 domains)
SYMP: SWB
HCU: Readm
PROCESS: Support
Sign. better on Activity
domain, other domains NS;
Sign. less anxiety (not
sustained), depression NS
NS
NS
NS
Garcia-Aymerich et al.,
2007
‘‘Integrated care
intervention’’
COPD patients recruited
in a tertiary hospitals
immediately after the
patients’ hospital
discharge for an
exacerbation >48 hours
(Spain).
RCT
Good
I: Provider education,
self-management,
continuity of care (case
management; follow-up)
(NZ44)
C: Usual care (NZ69)
12 LUNG: FEV1
QOL: SGRQ; EQ-5D
SYMP: Dyspnoea
PROCESS: Knowledge;
Compliance; Behaviour
NS
NS; NS
NS
All variables related to
knowledge and behaviour
were better, mostly sign.;
Compliance NS
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Herborg et al., 2001
‘‘Community-Based
Programme for
Pharmaceutical Care’’
Asthma patients aged
16e60 who purchased
medication at the
participating community
pharmacies in the area
(Denmark)
CBA
Good
I: Provider education,
patient education,
expansion or revision of
professional roles
(pharmacist plays more
active role in patient
monitoring)/monitoring
system (NZ264)
C: Usual care (NZ236)
12 LUNG: PEFR
QOL: NHP; LWAQ
SYMP: Asthma Symptom
Status
QOC: Satisfaction
HCU: ED; Hosp; Visits
PROCESS: Knowledge;
Compliance
NS
Sign. more improvement
on both measures
Sign. better improved
asthma status
NS
NS; NS; Clinically relevant
less use of services
Sign. more knowledge on
asthma (medications);
Sign. less inhalation errors
Hermiz et al., 2002
‘‘Home-Based Care by
Community Nurse‘‘
COPD patients in Health
Services 30e80 years,
attended to ED or
admitted to the hospitals
(Australia)
RCT
Moderate
I: Patient education,
continuity of care
(follow-up) (NZ84)
C: Usual care (NZ93)
3 QOL: SGRQ
QOC: Satisfaction
HCU: Hosp; ED
PROCESS: Knowledge;
Behaviour; Follow
NS
Sign. more satisfied with
their care
NS; NS
Sign. greater knowledge of
COPD; NS; Sign. more
follow-up
Hernandez et al., 2003
‘‘Home Hospitalisation’’
COPD patients with
exacerbations admitted
to ER or two tertiary
hospitals (Spain)
RCT
Moderate
I: Provider education,
self-management,
continuity of care
(follow-up) (NZ121)
C: Usual care (NZ101)
2 QOL: SGRQ (4 domains)
QOC: Satisfaction
HCU: Readm; ED; LOS;
Cost
PROCESS: Knowledge;
Compliance
Sign. higher improvement
in Total score
Sign. higher satisfaction
NS; Sign. less ED
admissions; Sign. lower
LOS; Sign. lower overall
health care cost per
patient
Sign. more improvement
in knowledge and
compliance to inhalation
technique
Hesselink et al., 2004
‘‘Education Programme’’
Patients aged 16e75
from GP practices in with
asthma or COPD (The
Netherlands)
RCT
Good
I: Patient education,
team changes
(professional roles;
nurse) (NZ139)
C: Usual care (NZ137)
12 QOL: QOL-RIQ
SYMP: MRC
PROCESS: Efficacy;
Technique; Coping;
Compliance; Behaviour
NS
NS
NS; Inhalation technique
was significantly better;
NS; NS; NS
24 QOL: QOL-RIQ
SYMP: MRC
PROCESS: Efficacy;
Technique; Coping;
Compliance; Behaviour
NS
NS
NS; Inhalation technique
was significantly better;
NS; NS; NS
(continued on next page)
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Table 2 (continued)
Study Setting Studya
design/quality
Interventions Follow-up
(months)b
Outcomec/process
indicatorsd
Resultse
Jeffs et al., 2005
‘‘Post Acute Respiratory
Outreach Service’’
All patients with COPD in
a regional hospital
(Australia)
CBA
Moderate
I: Patient education,
continuity of care
(follow-up) (NZ28)
C: Usual care (NZ25)
12 HCU: ED; Hosp; LOS NS; NS; Sign. higher
increase in hospital bed
days
Johnson et al., 2005,2007
‘‘Disease Management’’
Patients in the McKesson
Asthma Care Support
Advisor program (U.S.)
CBA
Moderate
I: Provider education,
self-management,
continuity of care (case
management) (NZ196)
C: Usual care (NZ196)
12 HCU: ED; Hosp;
LOS; Adm
PROCESS: Compliance
Sign. fewer ED visits,
hospitalisations, bed days,
and asthma-related
admissions.
Sign. higher rates of
medication usage
Knoell et al., 1998
‘‘Outpatient
Pharmaceutical Care’’
Adult asthma patients
referred to a specialty
outpatient clinic (U.S)
CBA
Moderate
I: Patient education,
team changes
(professional roles/
pharmacist) (NZ45)
C: Usual care (NZ55)
3 QOL: SF12; AQLQ
QOC: Satisfaction
HCU: Hosp; ED;
Visits; Cost
PROCESS: Compliance;
Process
NS; sign. more
improvement in quality of
life
Sign. more satisfaction
with care
NS: NS; NS; NS
Sign. more compliant and
better informed patients
Kritikos et al., 2007
‘‘Interactive Small-group
Education in a Community
Pharmacy Setting’’
Asthma patients 16
registered in a pharmacy
in the Central Sydney
Area (Australia)
RCT
Moderate
I: Provider education,
patient education,
expansion or revision of
professional roles
(pharmacist plays more
active role in patient
monitoring) (NZ16)
C: Usual care (NZ16)
3 SYMP: Asthma control
QOL: AQLQ
PROCESS: Knowledge;
Technique; Compliance
Sign. less patients in the
severe asthma/poor
control category
Sign. more improvement
in quality of life
Sign. higher asthma
knowledge scores; Sign.
more increase of correct
inhalation technique; NS
Lee et al., 2002
‘‘Care Protocol by
Community Nurses’’
COPD patients 65,
resident of 45 nursing
homes in Hong Kong
(China)
RCT
Moderate
I: Provider education,
self-management,
continuity of care
(follow-up) (NZ48)
C: Usual care (NZ41)
6 LUNG: FEV1
QOL: GHQ (4 domains);
Barthel Index (BI)
QOC: Satisfaction
HCU: ED; Hosp; LOS
NS
Sign. less anxiety and
insomnia and sign.
improved overall
psychological well-being;
NS
Sign. more increase in
level of satisfaction
NS; NS; NS
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McLean et al., 2003
‘‘Community Pharmacy
Programme’’
Uncontrolled asthma
patients in from
pharmacies in the
community (Canada)
RCT
Good
I: Patient education,
team changes
(professional roles/
pharmacist) (NZ191)
C: Usual care (NZ214)
12 LUNG: PEFR
QOL: AQLQ (4 domains)
SYMP: Dyspnoea; cough;
wheeze; phlegm
HCU: ED; Hosp; Days off;
Visits
PROCESS: Knowledge;
Compliance
Sign. improvement in
mean PEFR
Sign. greater improvement
in all domains
Sign. greater improvement
in all symptoms
NS; NS; NS; Sign. reduction
in No. of medical visits
Sign. greater improvement
in knowledge and
compliance
Mehuys et al., 2008
‘‘Pharmacist Intervention
for Asthma Control’’
Asthma patients 18e50
registered in
pharmacies, located in
diverse areas of Flanders
(Belgium)
RCT
Moderate
I: Provider education,
patient education,
expansion or revision of
professional roles
(pharmacist plays more
active role in patient
monitoring) (NZ107)
C: Usual care (NZ94)
6 QOL: AQLQ
SYMP: Asthma Control
Test (control, rescue
medication,
awakenings);
Exacerbations
PROCESS: Compliance;
Technique; Knowledge;
Behaviour
NS
NS, Sign. higher reduction
in need of rescue
medication, Sign. less
night-time awakenings; NS
Sign. higher adherence to
controller medication;
Sign. better inhalation
technique; NS; NS
Meulepas et al., 2007
‘‘Integrated primary care
management model’’
COPD patients 40 in
general practice (The
Netherlands)
CBA
Moderate
I: Patient education,
team changes
(professional roles;
nurse) (NZ137)
C: Usual care (NZ123)
24 SYMP: Exacerbations
PROCESS: Process;
Technique; Compliance
NS
Sign. more improvement
of No. of planned visits
and periodical lung
function measurement;
Sign. more improvement
in correct inhalation
technique; NS
Pilotto et al., 2004
‘‘Nurse-Run Asthma
Clinics’’
Asthma patients aged
18 years attended
nurse-run asthma clinics
(Australia)
RCT
Good
I: Patient education,
continuity of care
(follow-up) (NZ80)
C: Usual care (NZ90)
9 LUNG: FEV1
QOL: SGRQ (4 domains)
HCU: ED; Hosp; Days off;
Visits
PROCESS: Behaviour
NS
NS
NS; NS; Sign. less time off
work; Sign. more hospital
outpatient department
visits
NS
(continued on next page)
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Table 2 (continued)
Study Setting Studya
design/quality
Interventions Follow-up
(months)b
Outcomec/process
indicatorsd
Resultse
Poole et al., 2001
‘‘Case Management’’
All patients who had
been admitted to
Auckland hospital for
COPD for 4 in the
previous 2 years (with 2
in the previous 12
months) (New Zealand)
CBA
Moderate
I: Provider education,
self-management,
continuity of care
(follow-up) (NZ16)
C: Usual care (NZ16)
12 QOL: CRQ (4 domains)
HCU: Hosp; LOS
Clinically relevant
improvement in all CRQ
scores and stat. sign. for
total and fatigue for
theintervention group (no
data control)
NS; Sign. more decrease in
LOS
Premaratne et al., 1999
‘‘Nurse specialists in
asthma management’’
All registered asthma
patients aged 15e50
years of 41 general
practices in Greenwich
with a practice nurse
(U.K.)
RCT
Moderate
I: Patient education,
team changes
(professional roles;
nurse) (NZ43436)
C: Usual care (NZ57932)
36 QOL: AQLQ
HCU: ED; Hosp
PROCESS: Compliance
NS
NS; NS
NS
Rea et al., 2004
‘‘Chronic Disease
Management’’
COPD patients from four
general practices (New
Zealand)
RCT
Moderate
I: Patient education,
continuity of care (case
management) (NZ83)
C: Usual care (NZ52)
12 LUNG: FEV1
QOL: SF36; CRQ (4
domains)
SYMP: SWT
HCU: Hosp; LOS
PROCESS: Compliance
Stat. but not clinically
sign. improvement
NS; Stat. and clinically
sign. improvement in 2
domains (fatigue,
mastery)
NS
NS; NS
NS
Rootmensen et al., 2008
‘‘Additional Pulmonary
Nurse Care’’
Asthma and COPD
patients 18 from the
pulmonary outpatient
clinic at the Academic
Medical Centre in
Amsterdam (the
Netherlands)
RCT
Good
I: Patient education,
continuity of care (case
management) (NZ97)
C: Usual Care (NZ94)
6 QOL: SGRQ; SF36
SYMP: Exacerbations
QOC: Outpatient
satisfaction
PROCESS: Knowledge;
Behaviour; Technique
NS; NS
NS
NS
Sign. higher increase in
knowledge; NS; NS
Schonlau et al., 2005
‘‘Quality Improvement
Collaborative’’
Asthma patients of 6
rural and urban asthma
clinics (U.S.)
CBA
Good
I: Provider education,
self-management,
continuity of care (case
management) (NZ101)
C: Usual care (NZ64)
12 QOL: SF12
QOC: Satisfaction
HCU: ED; Days off
PROCESS: Knowledge;
Behaviour; Compliance;
Process
NS
Sign. more likely to be
satisfied with clinician
NS; NS
NS; Sign. better self-
management; NS; Sign.
Process improvement
680
K
.M
.M
.
Le
m
m
e
n
s
e
t
a
l.
Schulz et al., 2001
‘‘Pharmaceutical Asthma
Care Services’’
Asthma patients
registered in a pharmacy
in the city of Hamburg
(Germany)
CBA
Moderate
I: Provider education,
patient education,
expansion or revision of
professional roles
(pharmacist plays more
active role in patient
monitoring) (NZ191)
C: Usual care (NZ205)
12 LUNG: FEV1; PEFR
SYMP: Dyspnoea
QOL: SF36 (2 domains);
LWAQ (11 domains)
PROCESS: Knowledge;
Technique; Efficacy
NS; NS
NS
Sign. more improvement
in mental scale, physical
scale NS; Sign. more
improvement in summary
and all subscales
Sign. more improvement
in knowledge, inhalation
technique and self-
efficacy
Smith et al., 2005
‘‘Home-Based Nurse-led
Psycho Educational
Intervention’’
Adult patients registered
at the asthma clinic
(U.K.)
RCT
Good
I: Patient education,
continuity of care
(follow-up) (NZ47)
C: Usual care (NZ45)
12 QOL: SF36 (2 domains);
LWAQ
SYMP: Asthma Symptom
Status
PROCESS: Behaviour;
compliance
Sign. more improvement
in mental health score,
physical functioning NS;
Sign. better asthma
quality of life score
NS
NS; Sign. more increase in
PEF monitoring
Solomon/Gourley 1998
‘‘Pharmaceutical
Care Model’’
Ambulatory COPD
patients >40 years of 10
departments of Veterans
Affairs medical centres
and 1 academic medical
centre (U.S.)
RCT
Moderate
I: Patient education,
team changes
(professional roles/
pharmacist) (NZ43)
C: Usual care (NZ55)
6 QOL: HSQ
SYMP: Dyspnoea
QOC: Satisfaction
HCU: ED; Hosp; Visits
PROCESS: Compliance;
Knowledge; Process
NS
NS
Sign. better satisfaction
NS; NS; NS
NS; NS; NS
Sridhar et al., 2008
‘‘Nurse-led intermediate
care package’’
COPD patients previously
admitted to community
and hospital care in west
London (U.K.)
RCT
Good
I: Patient education,
continuity of care
(follow-up) (NZ61)10.
C: Usual care (NZ61)
24 SYMP: Mortality
QOL: CRQ (4 domains)
SYMP: Exacerbations
HCU: Hosp; Visits; Cost
PROCESS: Behaviour
Sign. lower No. of COPD-
related deaths
NS
NS
NS; Sign. less unscheduled
GP contacts; NS
Sign. better self-
management of
exacerbations
(continued on next page)
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Table 2 (continued)
Study Setting Studya
design/quality
Interventions Follow-up
(months)b
Outcomec/process
indicatorsd
Resultse
Vrijhoef et al., 2007
‘‘Transfer of Care’’
Patients with previously
documented COPD
attending the respiratory
outpatient clinic (The
Netherlands)
RCT
Good
I: Provider education,
patient education, team
changes (professional
roles; nurse), continuity
of care (follow-up)
(NZ 91)
C: Usual Care (NZ83)
9 LUNG: FEV1; FVC
QOL: SGRQ; COOP/
WONCA
QOC: Satisfaction
HCU: Visits
PROCESS: Behaviour;
Knowledge
NS; Sign. more
improvement in mean FVC
NS; NS
Sign. better satisfaction
NS
Self care behaviour was
mostly NS with exception
of sign. better coping and
sign. lower condition
maintenance; Sign. bigger
improvement of
knowledge
Weinberger et al., 2002
‘‘Pharmaceutical Care
Programme’’
Asthma and COPD
patients >18 years with
reactive airways disease
at 36 community
drugstores in
Indianapolis (U.S)
RCT
Good
I: Provider education,
patient education,
expansion or revision of
professional roles
(pharmacist plays more
active role in patient
monitoring) (NZ447)
C: Usual care (NZ303)
12 LUNG: PEFR
QOL: CRQ; AQLQ
QOC: Satisfaction
HCU: ED; Hosp
PROCESS: Process
Sign. higher peak flow
rates
NS (COPD); NS (asthma)
Sign. more satisfied with
pharmacist
NS; NS (COPD); Sign. more
breathing-related ED and
hospital visits (asthma)
NS
Multiple interventions versus single intervention
Donald et al., 2008
‘‘Telephone based
Asthma Management’’
Adults aged 18e55 years
admitted to one or both
of two metropolitan
Melbourne (Victoria)
teaching hospitals with a
primary diagnosis of
asthma (Australia)
RCT
Moderate
I: Patient education,
continuity of care
(follow-up) (NZ36)
C: Patient education
(NZ35)
12 LUNG: Morbidity
HCU: ED; Readm; Visits
NS
NS; Sign. less
readmissions; NS
Coultas et al., 2005
‘‘Nurse-Assisted
Home Care’’
COPD patients in primary
care clinics associates
with an urban academic
health center, aged 45
cared for by primary care
physicians (U.S.)
RCT
Moderate
I: Provider education,
patient education,
continuity of care
(follow-up) (NZ72)
C: Patient education
(NZ72)
6 QOL: SF36; SGRQ; Illness
intrusiveness scale
HCU: ED; Hosp; Visits
NS; NS; NS
NS; NS; NS
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Schatz et al., 2006
‘‘Care Manager’’
Asthma patients 18e56
of the San Diego Kaiser
Permanente Medical
Care Programme (U.S.)
RCT
Moderate
I: Patient education,
continuity of care
(follow-up/case
management) (NZ31)
C: Patient education
(NZ31)
12 QOL: AQLQ
SYMP: Symptom free
days
PROCESS: Knowledge
NS
NS
Sign. better rating of
asthma knowledge
Smith et al., 1999
‘‘Respiratory Home
Nurse Intervention’’
Patients >40 years with
severe COPD attending a
teaching hospital
(Australia)
RCT
Moderate
I: Patient education,
continuity of care
(follow-up) (NZ48)
C: Patient education
(NZ48)
12 LUNG: FEV1
QOL: COOP
HCU: Hosp; Visits; LOS
Sign. deterioration (no
data control)
Sign. improvement in total
quality of life (no data
control)
NS; NS; NS
Weinberger et al., 2002
‘‘Pharmaceutical
Care Programme’’
Asthma and COPD
patients >18 years with
reactive airways disease
at 36 community
drugstores in
Indianapolis (U.S)
RCT
Good
I: Provider education,
patient education,
expansion or revision of
professional roles
(pharmacist plays more
active role in patient
monitoring) (NZ447)
C: Patient education
(NZ363)
12 LUNG: PEFR
QOL: CRQ; AQLQ
QOC: Satisfaction
HCU: ED; Hosp
PROCESS: Process
NS
NS (COPD); NS (asthma)
Sign. more satisfied with
pharmacist
NS; NS
NS
a Research designs: RCT: Randomised Controlled Trial; CBA: Controlled Before-After study.
b When the follow-up period is longer then 12 months, the 12-months results as well as the final results are presented.
c Outcome indicators: Main: LUNG Z lung function; QOL Z quality of life; SYMP: symptoms; QOC: quality of care; HCU: health care utilisation. Measures: FEV1Zforced expiratory
volume in 1 second; PEFRZpeak expiratory flow rate; MRCZMedical Research Council; ExacerbationsZ number of exacerbations; SWBZSubjective Well-Being; 6MWDZ6-Minute Walking
Distance; SWTZShuttle Walk Test; CRQZChronic Respiratory Questionnaire; SGRQZSt. George’s Respiratory Questionnaire; QWBZQuality of Well-being Scale; SF36/12ZShort-Form 36/
12; NHPZNottingham Health Profile; COOP/WONCAZ; LWAQZ Living With Asthma Questionnaire; QOL-RIQZQuality-of-life for Respiratory Illness Questionnaire; AQLQZAsthma Quality
of Life Questionnaire; GHQ Z General Health Questionnaire; HSQ Z Health Status Questionnaire; VASZVisual Analogue Scale; EQ-5DZEuro-Quol-5D; HADSZHospital and Anxiety
Depression Scale; ED Z number of emergency department visits; HospZnumber of hospitalisations; Days off Z number of days off work/school; VisitsZnumber of visits to health care
services; (Re)adm Z number of (re)admissions; LOSZlength of stay; Cost Z costs.
d Process indicators: Main: PROCESSZProcess indicators. Measures: BehaviourZ self-management behaviour; ComplianceZ (medication) compliance; KnowledgeZpatient knowledge;
EfficacyZself-efficacy; TechniqueZinhalation technique; SupportZsocial support; ProcessZprocess performed; FollowZfollow-up.
e All results are presented compared to ‘‘usual care’’.
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684 K.M.M. Lemmens et al.quality of life differed widely among the studies. Reported
clinical outcomes, lung function and symptoms, generally
demonstrated no significant differences between inter-
vention and control groups. But, studies directed at asthma
patients frequently showed a significant decline in
symptoms.48,53,60,70,71 Various studies reported quality of
care measures (satisfaction), a great variety of instruments
found mostly significant beneficial differences for multiple
interventions. Significant improvements on process
measures were reported, as well. Improved compliance,
enhanced knowledge, and inhalation technique were
frequently found, often combined with significant
improvement in quality of care.
Patient education in combination with case
management (and professional education)
Nine studies examined patient education in combination
with case management compared to usual
care51,56,61,64,73,77,78,82,84 showing mixed results. We noted
an apparent variation in intensity and duration of theStudy or Subgroup
 Double interventions versus Usual Care
Bourbeau
Hermiz
Pilotto
Subtotal (95% CI)
Heterogeneity: Chi2 = 1.58, df = 2 (P = 0.45); I2 = 0%
Test for overall effect: Z = 0.57 (P = 0.57)
 Triple interventions versus Usual Care
Coultas
Garcia-Aymerich
Vrijhoef
Subtotal (95% CI)
Heterogeneity: Chi2 = 2.02, df = 2 (P = 0.36); I2 = 1%
Test for overall effect: Z = 2.39 (P = 0.02)
Total (95% CI)
Heterogeneity: Chi2 = 5.64, df = 5 (P = 0.34); I2 = 11%
Test for overall effect: Z = 2.00 (P = 0.05)
Test for subgroup differences: Chi2 = 2.04, df = 1 (P = 0.15), I2 = 51.0%
Mean
50.6
59.39
27
55
37.5
28.1
SD
17.8
20.3
15.9
16.4
22.3
15.1
Total
81
67
71
219
51
20
81
152
371
Mean
54.2
57.68
27.3
58.5
49.8
31.8
SD
17.6
19.75
17.1
16.4
18.4
16.6
Total
76
80
82
238
51
41
69
161
399
Weigh
19.9%
14.4%
22.3%
56.7%
15.1%
4.8%
23.4%
43.3%
100.0%
Multiple Usual Care
Study or Subgroup
 Double interventions versus Usual Care
Bourbeau
Hermiz
Pilotto
Subtotal (95% CI)
Heterogeneity: Chi2 = 0.19, df = 2 (P = 0.91); I2 = 0%
Test for overall effect: Z = 0.39 (P = 0.70)
 Triple interventions versus Usual Care
Coultas
Garcia-Aymerich
Vrijhoef
Subtotal (95% CI)
Heterogeneity: Chi2 = 3.02, df = 2 (P = 0.22); I2 = 34%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI)
Heterogeneity: Chi2 = 3.45, df = 5 (P = 0.63); I2 = 0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 = 0%
Mean
57.2
66.04
36.9
59.8
28.6
37.2
SD
20.9
19.9
24.3
14.7
24.8
24.9
Total
81
67
71
219
51
21
84
156
375
Mean
56.9
67.65
37.8
61.4
40.5
36.4
SD
18.7
17
21.1
16.5
19.8
25.6
Total
76
80
82
238
51
41
75
167
405
Weigh
21.3%
22.3%
15.5%
59.1%
22.2%
5.5%
13.2%
40.9%
100.0%
Multiple Usual Care
a
binterventions, ranging from home visits after 1 and 4 weeks
to weekly calls and monthly visits for 1 year. Similarly,
duration of the follow-up period largely varied; from
6 weeks to 2 years.
Most of these studies reported quality of life parame-
ters51,56,61,73,77,82,84; three studies reported significant
beneficial differences for multiple interventions. Bourbeau
et al.51,57 found statistically and clinically significant
differences on the SGRQ impact and total score at 4 months
favouring the intervention group, whereas at 12 months
only the impact score reached clinical significance. Egan
et al.56 showed significant improved scores for the activity
domain of the SGRQ and the anxiety dimension of the HADS
in the intervention group. Smith et al.82 reported evidence
of significant effects on asthma specific quality of life and
SF-36 mental subscales at 12 months, no results were found
on SF-36 physical subscales. Six studies evaluated the
impact of the interventions in terms of changes in health
care utilisation.51,56,61,64,73,84 Only the study by Gadoury
et al.57 revealed strong indications for improvements in
health care utilisation, i.e. statistically significant andt IV, Fixed, 95% CI
-3.60 [-9.14, 1.94]
1.71 [-4.80, 8.22]
-0.30 [-5.53, 4.93]
-0.95 [-4.23, 2.34]
-3.50 [-9.87, 2.87]
-12.30 [-23.58, -1.02]
-3.70 [-8.81, 1.41]
-4.59 [-8.34, -0.83]
-2.52 [-5.00, -0.05]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
t IV, Fixed, 95% CI
0.30 [-5.90, 6.50]
-1.61 [-7.66, 4.44]
-0.90 [-8.17, 6.37]
-0.74 [-4.45, 2.98]
-1.60 [-7.66, 4.46]
-11.90 [-24.12, 0.32]
0.80 [-7.07, 8.67]
-2.20 [-6.68, 2.27]
-1.34 [-4.20, 1.52]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours multiple
Favours usual careFavours multiple
Favours usual care
Disease-management interventions in asthma and COPD 685clinically relevant reduction of emergency room visits and
hospitalisations over a 2 year period. None of the other
studies detected statistical significant changes on these
parameters.
Eleven studies examined patient education and case
management in combination with professional educa-
tion.47,52,54,58,62,65,69,74,76,79,85 All but two studies con-
cerned COPD care. Quality of life measures were reported
in most studies. Four studies reported improvement on the
SGRQ score in favour of the multiple intervention groups,
however not constantly significant. Rea et al.76 reported
a significant improvement for two dimensions of the CRQ
(fatigue and mastery), but no significant difference was
found on the SF-36 score. Conversely, another study by
Aiken et al.47 showed better physical functioning, vitality
and total function on the SF-36 in favour of the intervention
group. Lee et al.69 showed a significant greater improve-
ment in psychological wellbeing (GHQ) in the intervention
group. Of the ten studies reporting health care utilisationStudy or Subgroup
 Double interventions versus Usual Care
Bourbeau
Hermiz
Pilotto
Subtotal (95% CI)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.95); I2 = 0%
Test for overall effect: Z = 0.08 (P = 0.94)
 Triple interventions versus Usual Care
Coultas
Garcia-Aymerich
Vrijhoef
Subtotal (95% CI)
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 = 0%
Test for overall effect: Z = 2.24 (P = 0.03)
Total (95% CI)
Heterogeneity: Chi2 = 3.50, df = 5 (P = 0.62); I2 = 0%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi2 = 2.65, df = 1 (P = 0.10), I2 = 62.3%
Mean
71.9
74.83
38.6
73.8
57.3
34.8
SD
19.3
23.46
23
18.3
27.8
20.8
Total
81
67
71
219
51
21
84
156
375
Mean
72.6
74.05
38.9
77.3
67.6
40.3
SD
19.5
22.33
24.9
18.3
22.8
21
Total
76
80
82
238
51
41
72
164
402
Weig
24.5
16.3
15.7
56.5
17.9
4.8
20.9
43.5
100.0
Multiple Usual Care
Study or Subgroup
 Double interventions versus Usual Care
Bourbeau
Hermiz
Pilotto
Subtotal (95% CI)
Heterogeneity: Chi2 = 4.08, df = 2 (P = 0.13); I2 = 51%
Test for overall effect: Z = 0.66 (P = 0.51)
 Triple interventions versus Usual Care
Coultas
Garcia-Aymerich
Vrijhoef
Subtotal (95% CI)
Heterogeneity: Chi2 = 2.48, df = 2 (P = 0.29); I2 = 19%
Test for overall effect: Z = 2.28 (P = 0.02)
Total (95% CI)
Heterogeneity: Chi2 = 8.14, df = 5 (P = 0.15); I2 = 39%
Test for overall effect: Z = 2.02 (P = 0.04)
Test for subgroup differences: Chi2 = 1.58, df = 1 (P = 0.21), I2 = 36.8%
Mean
36.3
48.48
17.3
43
29.5
21.1
SD
20.3
23.43
14
19.6
22.6
13.5
Total
81
67
71
219
51
20
81
152
371
Mean
42.8
45.22
17.4
47.3
42.5
24.1
SD
21.4
23.06
15.4
19.3
19.2
15.7
Total
76
80
82
238
51
41
69
161
399
Weigh
14.9%
11.2%
29.4%
55.5
11.2%
4.8%
28.5%
44.5
100.0
Multiple Usual Care
c
d
Figure 2 Multiple interventions including case management versu
B: symptoms; C: activity; D: impact).three studies52,62,65 demonstrated significant reductions in
readmissions and emergency department visits.
Overall, no significant differences between intervention
and control groups were found on clinical outcomes, namely
lung function and symptoms. Reports on satisfaction showed
significant more increase in satisfaction in intervention
groups compared to control groups. Processes measures also
showed positive results: most studies reported significantly
better scores on knowledge and self-management in the
intervention groups.
Meta-analyses demonstrated statistically significant
improvements on the SGRQ total and impact scores in favour
of multiple interventions (Fig. 2). The differences on the
SGRQ activity score reached statistical significance in the
triple intervention studies. Pooled SGRQ data showed better
effects in triple intervention compared to double interven-
tion studies. Moreover, clinically relevant differences for
triple interventions were found in SGRQ total, activity and
impact scores. No significant difference or clinically relevantht
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s usual care, quality of life (SGRQ) post intervention (A: total;
Study or Subgroup
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Rea
Total (95% CI)
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Heterogeneity: Chi2 = 2.81, df = 4 (P = 0.59); I2 = 0%
Test for overall effect: Z = 2.96 (P = 0.003)
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Figure 3 Multiple interventions including case management versus usual care, hospital admissions.
686 K.M.M. Lemmens et al.was found on the SGRQ symptom score. Nine studies
reporting hospitalisations in COPD-care were pooled (Fig. 3).
For a few studies standard deviations were not avail-
able,56,62,77 however they did show similar mean scores.
There was a statistically significant reduction of the
probability of at least one hospital admission among
patients receiving multiple interventions compared to usual
care. Data on double interventions showed statistical
heterogeneity (I2Z 67.4%) and were therefore excluded
from further analyses. Subgroup analyses of triple inter-
ventions revealed a significant effect. Meta-analysis of
emergency department visits per person did not show
a statistically significant effect in favour of treatment
(Fig. 4). The level of statistical heterogeneity for this
outcome was related to the outlying effect reported in
Bourbeau57 (only double intervention); its removal led to
a lower I2 statistic (93.7% versus 21.2%).
Patient education in combination with revision of
professional roles (and professional education)
Six studies focussed on patient education as well as on
revision of professional roles. Two forms of revision could
be distinguished: substitution of physicians by nurses63,72,75
and pharmacists providing (drug) counselling that was
formerly provided by nurses and physicians.67,70,83 Substi-
tution of physicians by nurses was not associated with any
significant benefits, other than process improvements
mainly of inhalation technique. Of the studies involving
a pharmacist, two studies67,83 showed significantly more
satisfaction with care. Knoell et al.67 also reported signifi-
cant between-group differences in quality of life and
process measures. Moreover, McLean and colleagues70
found significant improvements on clinical, quality of life
and all process measures, but could not detect significantStudy or Subgroup
Aiken
Coultas
Hernandez
Lee
Total (95% CI)
Heterogeneity: Chi2 = 3.81, df = 3 (P = 0.28); I2 = 21%
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Figure 4 Multiple interventions including case management versudifferences on health care utilisation between groups. They
applied intense patient education: at least three 1-h
appointments every 2 or 3 weeks, followed by 1-h sessions
every 3 months.
Interventions in another eight studies constituted of
professional and patient education in combination with
pharmacists playing a more active role in patient moni-
toring.48,49,53,60,68,71,80,86 All studies concerned asthma
patients, apart from one study which focussed on both
diseases. The numerous outcomes measured showed posi-
tive results: in the intervention groups significantly better
symptom scores, quality of life scores and improvement in
process indicators, such as knowledge and inhalation
technique, were found in most studies. Overall, no signifi-
cant improvements were found in lung function. Results on
health care utilisation and satisfaction were ambiguous.
Meta-analysis of studies that included a pharma-
cist67,70,71,86 demonstrated a significant improvement on
the Asthma Quality of Life Questionnaire (AQLQ) (Fig. 5).
However, statistical heterogeneity was apparent. Subgroup
analyses showed a significant effect of double interven-
tions.67,70 Triple interventions71,86 compared to usual care
did not reach statistical significance. Yet, a qualitative
comparison on all quality of life instruments and other
outcomes suggest more significant effects of triple rather
than double interventions. Data measured by the Living
With Asthma Questionnaire (LWAQ)53,60,80 could not be
pooled due to instrument differences, caused by use of an
adjusted version of the original; all studies reported
significantly improved outcomes.
Multiple versus single interventions
In five studies multiple interventions were compared to
single interventions.54,55,78,81,86 Four studies reportedt
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Figure 5 Multiple interventions including a pharmacist versus usual care, quality of life (AQLQ) at 6 months.
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however non-significant, quality of life in the multiple
intervention group. Data on quality of life could not be
included in a meta-analysis due to heterogeneity of
instruments. Data reported on other outcomes in these
studies was too diverse to interpret.
Discussion
This study was performed to understand the effectiveness
of multifaceted disease management interventions in
improving care or reducing costs for patients with asthma
or COPD. Although relevant reports are limited in number
and show great heterogeneity, some cautious conclusions
can be drawn. The studies showed significant improvements
on quality of life in pharmacist programmes and COPD care
programmes. Qualitative analyses of other quality of life
measures partially confirmed this finding. Meta-analyses on
hospitalisations showed a significant reduction in the
number of patients with one or more hospital admissions
within triple interventions. No effects were found in
emergency department visits per person. Qualitative
assessment of the studies showed significant improvements
in process measures in several studies. Moreover, for
satisfaction, a positive trend was seen. Inconclusive results
were reported on symptoms; no effects were found in lung
function.
In particular, combining patient and professional
education with an active role of the pharmacist in patient
monitoring led to improvements in patient outcomes as
compared with usual care. Bravata et al.87 also reported
statistically significant improvements in processes and
outcomes when pharmacists were actively involved.
Education provided by pharmacists rather than by nurses
seemed to achieve better results. Taylor et al.88 also found
little evidence to support nurse-led management of COPD
patients in the community. A factor contributing to this
effect might be the lower intervention intensity of nurse
education compared with pharmacist education. Overall
the provision of education as a result of revision of roles
seemed to have a positive impact on patient satisfaction.This review included asthma as well as COPD studies;
these differed in several respects. Asthma studies focused
on adult patients from the age of 16 years; in some cases
the population was constrained to a maximum age. Studies
with regard to COPD patients, on the other hand, mostly
restricted their populations to older patients, from the age
of 30 years. All asthma studies were in community settings;
COPD studies took place in various settings. Results on
asthma seemed to achieve more favourable results of
multiple interventions than COPD studies, albeit not
consistently across all studies.
The multifaceted interventions also targeted various
populations ranging from mild to severe patients. It was
apparent that studies including more severe patients
showed greater tendency to success on the short run.
Another recurring theme was that studies that reported
a positive effect on quality of life often concerned pro-
grammes with more intense interventions of longer dura-
tion. This supports the continuous character of disease
management: multifaceted interventions should frequently
interact with the patients therein; the chronic care model
approach provides a promising manner to shape long-term
care for chronic patients.
The complexity of multiple disease management inter-
ventions makes rigorous evaluation and determining their
practical feasibility quite problematic. Although RCTs are
the gold standard in clinical research, in organisational
research it is difficult to set up RCTs.89 In general, a design
should be chosen that minimises potential bias (internal
validity) and maximises generalisability (external val-
idity).90e92 Therefore, this review concentrated on quasi-
experimental and experimental study designs. It was
apparent that many studies that failed to meet the quality
criteria on research methodology, concerned asthma
disease management studies.43e45 In these studies, partic-
ipants were offered commercial disease management pro-
grammes. However, using total costs as the primary
outcome measure to demonstrate programme effectiveness
and return on investment poses a significant threat to the
validity of outcomes in the evaluation of disease
management.93
688 K.M.M. Lemmens et al.While almost all studies measure outcome parameters,
less attention is paid to structure and process indicators.
Since multifaceted interventions interfere in the structure
and the process of care delivered, these are important
aspects to be measured. Nevertheless, nine studies did not
report process measures and merely one study reported
structure measures. For example, geographical differences
reflected in diverse organisational structures are considered
to influence the design and performance of the programmes.
Wewould like tomake a plea for more attention to the use of
structure and process parameters, as well as to considerable
(minimum) duration of data collection. Although the major
effects of disease management interventions may be
expected to occur in the long-term, the follow-up period in
15 of 36 studies was less than 1 year after allocation of the
subjects or start of the interventions. Sixteen studies lasted
12 months. No studies reported simulation models to
extrapolate measurements over time.
Limitations of the study
As with all systematic reviews, this study has several limi-
tations. Most importantly, it may be criticised for the
widely ranging quality and heterogeneity of the original
studies. These encompass a wide range in (combinations of)
interventions used, process and outcome variables, and
patient populations. Programme interpretation according
to the EPOC criteria was hampered by the imprecise
descriptions of the interventions. Next to that, lack of data
impeded the determination of the incremental benefits of
the various components of each intervention. Moreover, an
informative description of each intervention is extremely
important in disease management, because of the
comprehensiveness and the complexity of disease
management interventions. Furthermore, the intensity of
the interventions was often unclear. When described,
various interventions could be characterised as being of low
intensity, in particular professional-directed interventions.
In many cases the intervention consisted of a minimal level
of education, which Grimshaw and colleagues advised
against.18 They concluded that occasional education had
only short-term effects. From a methodological point of
view, restrictions in search strategies, such as databases,
could have influenced the study findings. Furthermore, the
absence of publication bias cannot be guaranteed. Conse-
quently, the effectiveness of combinations of interventions
may appear too positive.
Practice and research implications
Measuring at outcome as well as process levels contributes
to a better understanding of ways to improve quality of
care. Measuring the process of care contributes to under-
standing heterogeneity in patient outcomes. In addition to
outcomes measures, process measures should be collected
in future research. Structure indicators are largely missing
in this literature review. Since most multifaceted inter-
ventions involve some form of organisational change
resulting in structural change, information about the
structure of healthcare is essential. Future research should
attempt to set up practical, multicentre clinical trials;a wider range of physicians and settings is bound to improve
external validity.94 International comparative studies can
gain a better understanding of the effects of disease
management in relation to the health care system.
A wide variety of indicators were used to evaluate the
interventions. The indicators in the studies included in this
review were frequently not related to the interventions
that were evaluated. This holds true for process measures
in particular: although present in many studies, they did
not cover the degree of successful implementation of the
interventions. A plea has been made, therefore, to choose
process indicators that are sensitive to the specific inter-
ventions and are associated with the expected changes in
outcomes of care.35
More research on the long-term effectiveness of multi-
faceted interventions is needed, as follow-up in most of the
studies in the present review was short. Lack of hard
evidence of effectiveness of multiple interventions may in
part be due to inadequate length of follow-up. To deal with
this issue, future studies need to evaluate sustainability of
multiple interventions on the longer-term. Finally, as vari-
ation in follow-up periods and reporting of data complicate
comparability of studies, we would recommend to stand-
ardising reporting periods and data sets.
Conclusions
Current evidence on disease management programmes in
asthma and COPD shows improvements in quality of life and
reductions in hospitalisations in triple interventions. No
effects on emergency department visits were found.
Qualitative analysis demonstrated small, albeit no consis-
tent, improvements in process and outcome indicators.
Estimates of the effectiveness of multifaceted interven-
tions are limited by the wide range of outcomes measured,
the diverging combinations of interventions, the different
study designs and the many different settings in which care
was delivered. Still, this review points at promising
combinations of interventions. Improvement in comparison
with usual care was notably found for interventions in
which pharmacists can liase with the patient and the
professional, provide education and play an active role in
patient monitoring.
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